Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.57 |
| ▸ | GABRR1 | P24046 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | GPR84 | Q9NQS5 | 4/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 2/20 | 0.36 |
| ▸ | CA2 | P00918 | 2/20 | 0.36 |
| ▸ | CA9 | Q16790 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | MMP2 | P08253 | 1/20 | 0.32 |
| ▸ | MMP9 | P14780 | 1/20 | 0.32 |
| ▸ | MMP12 | P39900 | 1/20 | 0.32 |
| ▸ | MMP13 | P45452 | 1/20 | 0.32 |
| ▸ | MMP14 | P50281 | 1/20 | 0.32 |
| ▸ | HMGCR | P04035 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8893904 | 1.00 | SLC22A6 (0.57) | SLC22A6GABRR1LMNAMAPTSMN1; SMN2 | |
| SCHEMBL2227091 | 1.00 | SLC22A6 (0.57) | SLC22A6GABRR1LMNAMAPTSMN1; SMN2 | |
| SCHEMBL17204173 | 1.00 | SLC22A6 (0.57) | SLC22A6GABRR1LMNAMAPTSMN1; SMN2 | |
| SCHEMBL1135965 | 1.00 | SLC22A6 (0.57) | SLC22A6GABRR1LMNAMAPTSMN1; SMN2 | |
| SCHEMBL30641549 | 1.00 | SLC22A6 (0.57) | SLC22A6GABRR1LMNAMAPTSMN1; SMN2 | |
| SCHEMBL30972500 | 0.87 | — | — | |
| SCHEMBL374298 | 0.87 | — | — | |
| SCHEMBL1405707 | 0.87 | — | — | |
| SCHEMBL2687087 | 0.87 | — | — | |
| SCHEMBL6453593 | 0.87 | SLC22A6 (0.75) | SLC22A6GABRR1LMNAMAPTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1619191-B1 | Process for producing optically active 2-[6-(hydroxymethyl)-1,3-dioxan-4-yl] acetic acid derivatives | KANEKA CORP (JP) | 2010-10-27 | — | — | EP | disclosed |
| EP-1394157-B1 | Process for the preparation of 3,5-dihydroxy substituted esters as intermediates for producing optically active 2-(6-(hydroxymethyl)-1,3-dioxan-4-yl) acetic acid dervatives | KANEKA CORP (JP) | 2007-10-17 | — | — | EP | disclosed |
| EP-1619191-A2 | Process for producing optically active 2-[6-(hydroxymethyl)-1,3-dioxan-4-yl] acetic acid derivatives | KANEKA CORPORATION (JP) | 2006-01-25 | — | — | EP | disclosed |
| US-6903225-B2 | Process for producing optically active 2-[6-(hydroxymethyl)-1,3-dioxan-4-yl]acetic acid derivatives | KANEKA CORPORATION (JP) | 2005-06-07 | — | — | US | disclosed |
| EP-1024139-B1 | PROCESS FOR THE PREPARATION OF OPTICALLY ACTIVE 2-(6-(HYDROXYMETHYL)-1,3-DIOXAN-4-YL) ACETIC ACID DERIVATIVES | KANEKA CORP (JP) | 2004-05-12 | — | — | EP | disclosed |
| EP-1394157-A2 | Process for the preparation of 3,5-dihydroxy substituted esters as intermediates for producing optically active 2-(6-(hydroxymethyl)-1,3-dioxan-4-yl) acetic acid dervatives | KANEKA CORPORATION (JP) | 2004-03-03 | — | — | EP | disclosed |
| US-20030040634-A1 | Process for producing optically active 2-[6-(hydroxymethyl)-1,3-dioxan-4yl]acetic acid derivatives | KANEKA CORPORATION (JP) | 2003-02-27 | — | — | US | disclosed |
| US-6472544-B1 | REACTING ACETIC ACID DERIVATIVE WITH AN ENOLATE, REDUCING WITH A MICROORGANISM, ACETALIZING IN PRESENCE OF ACID CATALYST THEN ALKALINE SAPONIFICATION; NO SPECIAL EQUIPMENT OR SUPER LOW TEMPERATURE REQUIRED; INEXPENSIVE STARTING MATERIALS | KANEKA CORPORATION (JP) | 2002-10-29 | — | — | US | disclosed |
| EP-1024139-A1 | PROCESS FOR THE PREPARATION OF OPTICALLY ACTIVE 2- 6-(HYDROXYMETHYL)-1,3-DIOXAN-4-YL]ACETIC ACID DERIVATIVES | KANEKA CORPORATION (JP) | 2000-08-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030040634-A1 | Process for producing optically active 2-[6-(hydroxymethyl)-1,3-dioxan-4yl]acetic acid derivatives | HAAO, APEH, AADAC | SLC22A6 2542/4885GABRR1 2963/4885LMNA 2150/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.